Lev’s Hereditary Angioedema Agent Cinryze Could Reach Market In Early 2008
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The latest "ultra-orphan" compound to reach FDA is Lev Pharmaceuticals’ C1-esterase inhibitor Cinryze for the acute treatment of hereditary angioedema. Lev submitted the biologic July 31.